Practice-Changing Trials in Gastrointestinal Cancers at ASCO 2025: A Critical Review and Clinical Context
{{output}}
The ASCO 2025 meeting featured several phase III trials with the potential to impact gastrointestinal cancer management. CheckMate 577 reported mature overall survival (OS) data for adjuvant nivolumab in esophageal/GEJ cancer; however, OS benefit was not stati... ...